Table 3 Odds ratios, OR (and 95 % CI) of prostate cancer by quintiles of TAC all foods, TAC from fruits and vegetables, Cancer of the Prostate Sweden
FRAP food only | Q1 | Q2 | Q3 | Q4 | Q5 | p-t rend |
All prostate cancer | 294/226 | 292/228 | 301/220 | 308/212 | 294/226 | |
Age and region adjusted OR | 1.00 | 1.02 (0.80–1.31) | 1.08 (0.84–1.39) | 1.11 (0.87–1.43) | 1.02 (0.79–1.31) | 0.76 |
Fully adjusted OR | 1.00 | 0.98(0.77–1.26) | 1.05 (0.82–1.35) | 1.09 (0.85–1.40) | 1.05 (0.82–1.36) | 0.53 |
Lethal prostate cancer | 51/226 | 49/228 | 49/220 | 42/212 | 41/226 | |
Age and region adjusted OR | 1.00 | 0.98 (0.63–1.51) | 1.01(0.65–1.56) | 0.91 (0.58–1.43) | 0.89 (0.57–1.43) | 0.58 |
Fully adjusted OR | 1.00 | 0.98 (0.63–1.53) | 0.98(0.63–1.53) | 0.92 (0.58–1.45) | 0.87 (0.55–1.39) | 0.52 |
Advanced prostate cancer | 94/226 | 103/228 | 95/220 | 102/212 | 105/226 | |
Age and region adjusted OR | 1.00 | 1.11 (0.78–1.55) | 1.04(0.74–1.47) | 1.20 (0.85–1.68) | 1.23 (0.88–1.73) | 0.20 |
Fully adjusted OR | 1.00 | 1.08 (0.77–1.53) | 1.02(0.72–1.44) | 1.18 (0.83–1.67) | 1.23 (0.87–1.74) | 0.21 |
Localized prostate cancer | 201/226 | 196/228 | 216/220 | 212/212 | 195/226 | |
Age and region adjusted OR | 1.00 | 1.01 (0.77–1.33) | 1.16 (0.89–1.53) | 1.11 (0.84–1.46) | 0.96 (0.73–1.26) | 0.90 |
Fully adjusted OR | 1.00 | 0.96 (0.73–1.27) | 1.12 (0.85–1.47) | 1.09 (0.82–1.43) | 1.00 (0.75–1.32) | 0.80 |
High-grade prostate cancer | 56/226 | 39/228 | 47/220 | 49/212 | 40/226 | |
Age and region adjusted OR | 1.00 | 0.72 (0.46–1.13) | 0.88(0.57–1.36) | 0.99(0.64–1.52) | 0.79(0.50–1.25) | 0.64 |
Fully adjusted OR | 1.00 | 0.68 (0.43–1.07) | 0.83(0.53–1.28) | 0.95(0.61–1.48) | 0.78(0.49–1.24) | 0.63 |
Low–grade prostate cancer | 134/226 | 139/228 | 136/220 | 146/212 | 138/226 | |
Age and region adjusted OR | 1.00 | 1.06 (0.78–1.44) | 1.07 (0.78–1.45) | 1.11 (0.81–1.50) | 0.99 (0.72–1.35) | 0.22 |
Fully adjusted OR | 1.00 | 1.02 (0.75–1.39) | 1.03 (0.76–1.41) | 1.09 (0.80–1.49) | 1.04 (0.76–1.42) | 0.74 |
FRAP fruit & vegetables | Q1 | Q2 | Q3 | Q4 | Q5 | p-trend |
All prostate cancer | 297/222 | 277/243 | 306/213 | 311/209 | 295/224 | |
Age and region adjusted OR | 1.00 | 0.84(0.66–1.08) | 1.06(0.82–1.36) | 1.09(0.85–1.39) | 0.97(0.76–1.25) | 0.50 |
Fully adjusted OR | 1.00 | 0.83(0.64–1.07) | 1.04(0.80–1.34) | 1.07(0.83–1.38) | 0.94(0.73–1.22) | 0.82 |
Lethal prostate cancer | 53/222 | 33/243 | 52/213 | 45/209 | 48/224 | |
Age and region adjusted OR | 1.00 | 0.57 (0.36–0.92) | 1.01 (0.65–1.54) | 0.91 (0.58–1.41) | 0.91 (0.59–1.41) | 0.74 |
Fully adjusted OR | 1.00 | 0.61 (0.38–0.99) | 1.13 (0.73–1.77) | 1.07 (0.67–1.71) | 1.02 (0.65–1.61) | 0.39 |
Advanced prostate cancer | 114/222 | 77/243 | 106/213 | 98/209 | 102/224 | |
Age and region adjusted OR | 1.00 | 0.64 (0.44–0.94) | 0.90(0.63–1.30) | 0.92(0.64–1.33) | 0.91(0.63–1.30) | 0.76 |
Fully adjusted OR | 1.00 | 0.65(0.46–0.93) | 1.01(0.72–1.41) | 1.01(0.71–1.42) | 0.96(0.68–1.35) | 0.49 |
Localized prostate cancer | 192/222 | 204/243 | 205/213 | 219/209 | 199/224 | |
Age and region adjusted OR | 1.00 | 0.93 (0.71–1.23) | 1.09 (0.83–1.44) | 1.15 (0.87–1.51) | 1.00 (0.76–1.32) | 0.67 |
Fully adjusted OR | 1.00 | 0.90 (0.68–1.18) | 1.04 (0.79–1.38) | 1.07 (0.81–1.42) | 0.94 (0.71–1.25) | 0.95 |
High-grade prostate cancer | 53/222 | 27/243 | 46/213 | 45/209 | 58/224 | |
Age and region adjusted OR | 1.00 | 0.47(0.28–0.77) | 0.88 (0.57–1.37) | 0.89 (0.57–1.39) | 1.08 (0.71–1.64) | 0.12 |
Fully adjusted OR | 1.00 | 0.49(0.30–0.82) | 0.93 (0.59–1.46) | 0.99 (0.62–1.57) | 1.13 (0.73–1.76) | 0.08 |
Low-grade prostate cancer | 129/222 | 149/243 | 140/213 | 150/209 | 124/224 | |
Age and region adjusted OR | 1.00 | 0.99 (0.73–1.34) | 1.06 (0.78–1.45) | 1.15 (0.85–1.57) | 0.91 (0.66–1.24) | 0.67 |
Fully adjusted OR | 1.00 | 0.94 (0.69–1.28) | 1.01 (0.73–1.38) | 1.09 (0.80–1.50) | 0.85 (0.62–1.18) | 0.46 |